Hangzhou Biotest Biotech (688767) Fundamentals 2026 — P/E 130.6x, Revenue Analysis | SniperIQ
Hangzhou Biotest Biotech (688767) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥5.0B, trading at ¥33.80 on the SHH. This SniperIQ fundamentals page covers Hangzhou Biotest Biotech's valuation (P/E 130.6x, P/B 2.1x), profitability (net margin 6.2%), revenue (¥448M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Hangzhou Biotest Biotech's market cap?
Hangzhou Biotest Biotech (688767) has a market capitalization of approximately ¥5.0B, trading at ¥33.80 on the SHH. Market cap moves with the live share price.
What is Hangzhou Biotest Biotech's P/E ratio?
Hangzhou Biotest Biotech's trailing twelve-month P/E ratio is 130.6x, with a price-to-book (P/B) of 2.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Hangzhou Biotest Biotech?
Hangzhou Biotest Biotech runs a net profit margin of 6.2%, a gross margin of 100.1%, and an operating margin of 7.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Hangzhou Biotest Biotech generate?
Hangzhou Biotest Biotech reported revenue of ¥448M for fiscal year 2025, with net income of ¥47M and earnings per share (EPS) of 0.32. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Hangzhou Biotest Biotech pay a dividend?
Hangzhou Biotest Biotech offers a trailing dividend yield of about 2.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Hangzhou Biotest Biotech financially healthy?
Hangzhou Biotest Biotech carries a debt-to-equity ratio of 0.00x and a current ratio of 14.11x, with a market beta of 0.71. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Hangzhou Biotest Biotech a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Hangzhou Biotest Biotech (688767) the key facts are: market cap ¥5.0B, P/E 130.6x, revenue ¥448M, 52-week range 30.4-50.98. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Hangzhou Biotest Biotech's full fundamentals live
Get Hangzhou Biotest Biotech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.